Ovary removal not tied to increased risk of death (Reuters, 25 November 2011)

Genetic defect disturbs salt handling and pushes up blood pressure levels (AlphaGalileo, 25 November 2011)

Everolimus plus octreotide LAR for treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): RCT (NeLM News Service, 25 November 2011)

28 Nov 2011

An international phase 3 study published in The Lancet assesses the use of Everolimus plus octreotide long-acting repeatable (LAR) in the treatment of low-grade or intermediate-grade neuroendocrine tumours.

Related Topics

Adrenal Diabetes Metabolism Obesity Cardiovascular Bone Endocrine-Disrupting Chemicals Endocrine-Related Cancer Neuroendocrinology Reproduction Steroid and Steroidogenesis Thyroid

Share this story

Top stories

Call for nominations for Awards Committee Chair
30 Oct 2024

James M Tanner Award - 2025 nominations open
30 Oct 2024

Would you like to host the BSPED annual meeting?
21 Oct 2024

Most read